Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Avasopasem for the Treatment of Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer with Progression on a CDK4/6 Inhibitor and Hormonal Therapy

Trial Status: approved

This phase I trial studies the side effects and best dose of avasopasem in treating patients with hormone receptor positive, HER2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) that is progressing while taking a medication called a CDK 4/6 inhibitor (palbociclib, ribociclib or abemaciclib). Avasopasem has been shown to suppress the growth of certain cancer cells in laboratory studies. It has also been previously studied in cancer patients receiving radiation. Adding avasopasem to standard CDK 4/6 inhibitors may control the growth of metastatic hormone receptor positive, HER2 negative breast cancer.